Better outcomes of organ transplantations

iCoat Medical is a pharmaceutical company that runs clinical development to reduce and prevent ischemia reperfusion injury. iCoat Medical’s product candidate iCM012, built on 25 years research and development in collaboration with leading academic institutions, has been developed to improve the outcome of organ transplantations. iCoat Medical has its headquarter in Stockholm and has operations in Uppsala, Lund, Malmö and Tsukuba.